Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Blood|October 29, 2020
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?Nirav N Shah, Kwang W Ahn, Carlos Litovich, et al.
Bone Marrow Transplantation|August 10, 2023
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioningShanze Arshad, Xi Fang, Kwang W Ahn, et al.
Military Medicine|September 3, 2014
Day of injury cognitive performance on the Military Acute Concussion Evaluation (MACE) by U.S. military service members in OEF/OIFMichael McCrea, Kevin Guskiewicz, Selina Doncevic, et al.
Transplantation and Cellular Therapy|September 21, 2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic TransplantationNarendranath Epperla, Kwang W Ahn, Manoj Khanal, et al.
Transplantation and Cellular Therapy|September 20, 2024
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell TransplantationOthman S Akhtar, Shanze Arshad, Qinghua Lian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell TransplantationNarendranath Epperla, Mehdi Hamadani, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 14, 2020
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic TransplantationMehdi Hamadani, Manoj Khanal, Kwang W Ahn, et al.
Blood|July 1, 2022
KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trialMichael A Pulsipher, Kwang W Ahn, Nancy J Bunin, et al.
Hematological Oncology|January 10, 2017
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" studyNarendranath Epperla, Mehdi Hamadani, Amanda F Cashen, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Pageof 3